Clinical trials
Metastatic Prostate Cancer clinical trials
Below are recruiting metastatic prostate cancer clinical trials, each written for real people, not researchers. We’re tracking 719 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07313241RecruitingPhase 2
Salvage radiation with hormone therapy for prostate cancer recurrence
This trial tests how well salvage radiation therapy works for prostate cancer that has come back after surgery. It looks at whether adding hormone therapy based on PSA response improves outcomes.
Dallas, TexasAges 18 years+ - NCT07298239RecruitingEarly Phase 1
CAR-NK cell therapy for advanced prostate cancer
This trial tests a new immune cell therapy (CAR-NK cells) made from a healthy donor's cells. It is designed to attack prostate cancer that has spread and become resistant to hormone therapy, especially if your cancer cells have the PSMA protein.
Beijing, 不限Ages 18 years+ - NCT07302763Recruiting
PET imaging to track prostate cancer changes
This study uses special PET scans (up to 4 times) to see how metastatic prostate cancer changes over time. It is for people whose cancer has spread and is still growing after hormone treatments, and who are planning to start chemotherapy or PSMA therapy.
Québec, QuebecAges 18 years+ - NCT07292168RecruitingPhase 1/Phase 2
Study of a new antibody for advanced tumors with FGFR1 protein
This trial tests an experimental antibody, OM-RCA-01, in people with advanced solid tumors that have high levels of a protein called FGFR1. It aims to see if the drug is safe and effective for those who have already tried other treatments.
Kazan'Ages 18 years+ - NCT07287150RecruitingPhase 2
Testing Inavolisib for advanced prostate cancer
This study tests a new targeted therapy called inavolisib for men with advanced, hormone-resistant prostate cancer that has spread. The drug may work by blocking a specific pathway that helps cancer grow. Participants must have already tried one second-generation hormone therapy and have a tumor sample available for testing.
Los Angeles, CaliforniaAges 18 years+ - NCT07276438Recruiting
Image-guided radiation therapy for localized prostate cancer
This trial tests a precise radiation technique that adapts to your body's daily changes. It may offer better outcomes for men with prostate cancer that hasn't spread outside the pelvic area.
Los Angeles, CaliforniaAges 18 years+ - NCT07260435RecruitingPhase 3
Shorter hormone treatment for low volume spread prostate cancer
This study tests whether a shorter course of a newer hormone pill (apalutamide or enzalutamide) works well for men whose prostate cancer has spread to just a few spots and who recently started standard hormone therapy. It may allow you to take medication for less time while still controlling the cancer.
AlkmaarAges 18 years+ - NCT07255664RecruitingPhase 1/Phase 2
TIL therapy for advanced colorectal or prostate cancer
This trial tests a new type of immunotherapy that uses your own white blood cells (TILs) to fight advanced colorectal or prostate cancer. You will have surgery to remove a tumor, then your TIL cells are grown in a lab and given back to you along with other treatments to boost your immune system.
FrankfurtAges 18 years+ - NCT07258407RecruitingPhase 1/Phase 2
TD001 for men with PSMA-positive metastatic prostate cancer
This trial tests a new drug, TD001, in men whose prostate cancer has spread and is no longer responding to standard hormone therapy. It aims to see if TD001 is safe and effective against tumors that show a specific marker called PSMA.
New Haven, ConnecticutAges 18 years+ - NCT07252726RecruitingPhase 4
Morning vs. evening dosing for metastatic breast or prostate cancer
This trial tests whether taking your hormone therapy and targeted pills in the morning or evening affects how well they work and how you feel. It is for people with metastatic breast or prostate cancer starting a specific hormone-based treatment combination.
Kitchener, OntarioAges 18 years+ - NCT07250542RecruitingPhase 2
Fasudil with immunotherapy for advanced prostate cancer
This trial tests a combination of fasudil hydrochloride and immunotherapy for men with metastatic castration-resistant prostate cancer that has stopped responding to chemotherapy and hormone therapy. The goal is to see if this new approach can help control the cancer.
NanjingAges 18–85 - NCT07241416RecruitingPhase 3
Rezvilutamide for metastatic hormone-sensitive prostate cancer
This trial tests a new drug, rezvilutamide, combined with standard hormone therapy for men with prostate cancer that has spread but still responds to hormone treatment. The goal is to see if this drug helps control the cancer longer than the usual treatment alone.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07244393RecruitingPhase 1
Combination therapy for advanced prostate cancer
This trial tests a new combination therapy for advanced prostate cancer that has stopped responding to standard hormone treatments. It combines a radioactive targeted treatment (Lutetium-177 DGUL) with an immunotherapy drug (pembrolizumab) to see if it can shrink tumors and slow the cancer's growth.
SeoulAges 19 years+ - NCT07244341RecruitingPhase 1
Valemetostat and darolutamide for advanced prostate cancer
This trial tests a new combination of two drugs (valemetostat and darolutamide) for men with metastatic castration-resistant prostate cancer that has worsened after prior treatment. The goal is to see if the combination can slow cancer growth.
La Jolla, CaliforniaAges 18 years+ - NCT07237269RecruitingPhase 2
Abiraterone/prednisone plus ADT for early prostate cancer
This trial tests adding abiraterone (a hormone therapy pill) and prednisone to standard hormone therapy (ADT) for prostate cancer that has spread to nearby lymph nodes but is too small to see on regular scans. The goal is to see if this combination works better than ADT alone.
Omaha, NebraskaAges 30 years+ - NCT07234981RecruitingPhase 2
Using PSMA-PET to guide less intense radiation for returning prostate cancer
This trial uses a special scan (PSMA-PET) to find where prostate cancer has returned after surgery. Then doctors give a lower dose of radiation only to that area, which may reduce side effects. It is for men whose PSA level is rising after prostate removal.
Omaha, NebraskaAges 30 years+ - NCT07227077Recruiting
Physical activity study for older cancer survivors with chronic pain
This study uses a smartphone program to encourage physical activity in older adults who have survived cancer and have ongoing pain. It aims to learn how to best help you move more and feel better.
Milwaukee, WisconsinAges 65 years+ - NCT07224009RecruitingPhase 2
Low dose naltrexone for fatigue in prostate cancer on hormone therapy
This trial tests if a low dose of the drug naltrexone can help reduce fatigue in men with prostate cancer who are currently receiving hormone therapy (ADT). It may offer a new way to manage tiredness during treatment.
Little Rock, ArkansasAges 18 years+ - NCT07223385RecruitingPhase 2
Heart health check for prostate cancer patients on ARPI therapy
This trial is for men with advanced prostate cancer who are taking ARPI therapy. It offers a special heart health consultation to help manage the increased heart risk that can come with these powerful cancer treatments.
Los Angeles, CaliforniaAges 45 years+ - NCT07222436Recruiting
Blood test for high-risk prostate cancer
This trial studies a blood test that looks for tumor DNA in men with high-risk or advanced prostate cancer. It may help doctors understand the cancer better and guide treatment decisions.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07230106RecruitingPhase 2
Study of 3 drugs for men with prostate cancer
This trial tests whether a combination of three new drugs (SHR3680, HS-20093, and SHR2554) can help slow or stop prostate cancer growth. It is for men who are already on hormone therapy and whose PSA level is still rising.
Nanjing, JiangsuAges 18–80 - NCT07223372Recruiting
Study on male hormone blocking drugs for prostate cancer in Australia
This study looks at how certain drugs (darolutamide, enzalutamide, apalutamide, or abiraterone) that block male hormones are used to treat men with prostate cancer that has spread. It aims to understand real-world treatment patterns in Australia.
Pymble, New South WalesAges 18 years+ - NCT07213674RecruitingPhase 3
A study of xaluritamig plus abiraterone for prostate cancer
This trial tests a new combination of two drugs (xaluritamig plus abiraterone) for men with a type of advanced prostate cancer that is no longer responding to hormone therapy but has not yet been treated with chemotherapy. The goal is to see if this combination works better than the standard options your doctor might choose.
Goodyear, ArizonaAges 18 years+ - NCT07216248RecruitingPhase 2
Smart monitoring for men with advanced prostate cancer
This study tests if a smartphone-based tracking system can help doctors decide when to change treatment for men with hormone-sensitive prostate cancer that has spread. It uses standard drugs (relugolix and an ARPI) and monitors PSA levels closely.
Salt Lake City, UtahAges 18 years+
Hear when a new Metastatic Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic prostate cancer?
- Yes. Clin2 currently lists 719 recruiting metastatic prostate cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic prostate cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic prostate cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Castration-resistant Prostate Cancer
- Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Prostate Cancer Metastatic Disease
- Metastatic Castrate Resistant Prostate Cancer (mCRPC)
- Metastatic Castration-Resistant Prostate Cancer Patients
- Non-metastatic Castration-resistant Prostate Cancer
- Metastatic Breast Cancer
- Metastatic Colorectal Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.